FDA Expands Approval of Osimertinib in Lung Cancer EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy Sep 25, 2024
Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic Actual rates for 2021 lagged behind projections Sep 25, 2024
Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan Sep 11, 2024
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC However, plinabulin plus docetaxel still "not ready for prime time," expert says Sep 10, 2024
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC Absolute improvement of almost 30%, doubling of duration of response with savolitinib Sep 10, 2024
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC Two-trial analysis shows about a 40% decreased risk of disease recurrence or death Sep 09, 2024
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC Novel agent nearly halved risk of progression as first-line therapy in phase III trial Sep 09, 2024
Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy Sep 09, 2024
Trial Questions Role of Dual Immunotherapy in First-Line NSCLC In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity Aug 22, 2024
Researchers Challenge USPSTF's Lung Cancer Screening Criteria Alternate criteria based on years of smoking has higher sensitivity and specificity, study says Aug 20, 2024
Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib Aug 20, 2024
Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests More data for discussion of controversial association between steroids, immunotherapy Aug 19, 2024
FDA Expands Durvalumab Label to Operable Lung Cancer PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery Aug 16, 2024
Cancer Screening Costs Over $43 Billion a Year in the U.S., Study Estimates Colorectal cancer screening accounted for 64% of the total amount Aug 05, 2024
FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials Committee unanimously backs mandating trial design to distinguish effects of therapy phases Jul 25, 2024
Vapers May Be Less Likely to Undergo Lung Cancer Screening "Former smokers who use e-cigarettes remain at increased risk of lung cancer," researchers say Jul 02, 2024
Real-World Analysis Identifies Meds Tied to Higher Risk of Liver Injury Case reports may not be as reliable, researchers say Jun 25, 2024
Court: Some Employers Can Exclude PrEP, Cancer Screenings From Insurance Coverage Not all preventive care recommended by the USPSTF is threatened by the narrow ruling, however Jun 24, 2024
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response Jun 20, 2024
Early Menopause Tied to Higher Risk of Respiratory Mortality Greatest risk observed for women with bilateral oophorectomy Jun 13, 2024
Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer Half of patients responded, but editorialists call for new directions in therapy development Jun 11, 2024
Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma Immunotherapy may have been given too late, researchers suggested Jun 10, 2024
Lung Cancer Screening Rates Remain Low in the U.S., Especially in the South But one study showed that patient navigation added to usual care may increase uptake Jun 10, 2024
Artery Inflammation and CV Events; Stepped Palliative Care for Lung Cancer Patients Also in TTHealthWatch: diets and medicine in IBS and active surveillance in prostate cancer Jun 08, 2024 podcast
Limited-Stage SCLC Gets a New Standard of Care With Consolidation Durvalumab Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group Jun 03, 2024
'Practice Changing' Trial for Inoperable Locally Advanced NSCLC EGFR testing now needed for all patients with stage III disease, experts say Jun 02, 2024
Virtual and In-Person Palliative Care Equally Beneficial in Advanced Lung Cancer No differences observed in quality of life metric, patient and caregiver satisfaction Jun 02, 2024
Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLC Unexpectedly offers a possible overall survival benefit, researchers say Jun 01, 2024
Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents China-based trial may present a hurdle to FDA approval, however Jun 01, 2024
Unprecedented PFS Results in ALK-Positive Lung Cancer Trial "We have not seen anything close to this," says expert May 31, 2024
Smoking Isn't the Only Source of Nicotine Addiction in Town Emerging data suggest pharmacological interventions may help patients quit vaping May 29, 2024
Psychostimulant No Help in Relieving Cancer-Related Fatigue No significant differences in outcomes between methylphenidate, placebo May 22, 2024
FDA OKs Novel BiTE Agent for Small Cell Lung Cancer First-in-class tarlatamab achieved a 40% ORR in previously treated extensive-stage SCLC May 16, 2024
Perioperative Nivolumab Boosts EFS in Resectable Lung Cancer CheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death May 15, 2024
Will AI Replace Radiologists, or Just Make Them Better Than Ever? Opinions differ on how much physicians should be embracing the technology May 14, 2024
Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC Trend towards better response rate, PFS compared with approved KRAS inhibitors May 01, 2024
EPA Bans Consumer Use of Toxic Chemical Known to Cause Liver, Lung Cancers Methylene chloride has killed at least 88 workers since 1980 Apr 30, 2024
White House Indefinitely Delays Plan to Ban Menthol Cigarettes Biden administration has delayed the final rule several times recently Apr 26, 2024
Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC The ALK inhibitor reduced the risk of recurrence or death by 76% versus chemotherapy Apr 19, 2024
Accelerated Aging Linked to Recent Increase in Early-Onset Solid Tumors Strength of association increased in more recent birth cohorts Apr 09, 2024